You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

CITALOPRAM HYDROBROMIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Citalopram Hydrobromide patents expire, and what generic alternatives are available?

Citalopram Hydrobromide is a drug marketed by Almatica, Mylan Pharms Inc, Aurobindo Pharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Pharm Assoc, Biovail Labs Intl, Amneal Pharms Ny, Apotex, Aurobindo, Cosette, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Pharms Ltd, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, and Torrent Pharms. and is included in thirty-four NDAs.

The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Citalopram Hydrobromide

A generic version of CITALOPRAM HYDROBROMIDE was approved as citalopram hydrobromide by AUROBINDO on October 28th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CITALOPRAM HYDROBROMIDE?
  • What are the global sales for CITALOPRAM HYDROBROMIDE?
  • What is Average Wholesale Price for CITALOPRAM HYDROBROMIDE?
Drug patent expirations by year for CITALOPRAM HYDROBROMIDE
Drug Prices for CITALOPRAM HYDROBROMIDE

See drug prices for CITALOPRAM HYDROBROMIDE

Drug Sales Revenue Trends for CITALOPRAM HYDROBROMIDE

See drug sales revenues for CITALOPRAM HYDROBROMIDE

Recent Clinical Trials for CITALOPRAM HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3
Haining Health-Coming Biotech Co., Ltd.Phase 2
Alphacait, LLCPhase 2

See all CITALOPRAM HYDROBROMIDE clinical trials

Pharmacology for CITALOPRAM HYDROBROMIDE
Medical Subject Heading (MeSH) Categories for CITALOPRAM HYDROBROMIDE
Anatomical Therapeutic Chemical (ATC) Classes for CITALOPRAM HYDROBROMIDE

US Patents and Regulatory Information for CITALOPRAM HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077037-003 Nov 5, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fosun Pharma CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077035-003 Oct 28, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Epic Pharma CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077045-002 Apr 29, 2005 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.